Xspray Pharma: Update after Dasynoc CRL - Redeye

Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc. Based on the currently available information, we expect a new PDUFA date in either Q2 or Q3 next year and have adjusted our fair value range accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/1130255/xspray-pharma-update-after-dasynoc-crl?utm_source=finwire&utm_medium=RSS